MedPath

NEPHROGENEX INC.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

2 Phases

Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (50.0%)
Phase 3
1 (50.0%)

Pyridorin in Diabetic Nephropathy

Phase 3
Terminated
Conditions
Diabetic Nephropathy
Diabetic Kidney Disease
Interventions
Drug: Placebo
First Posted Date
2014-06-05
Last Posted Date
2016-03-09
Lead Sponsor
NephroGenex, Inc.
Target Recruit Count
328
Registration Number
NCT02156843
Locations
🇺🇸

CSG Investigational Site (#157), Birmingham, Alabama, United States

🇺🇸

CSG Investigational Site (#130), Phoenix, Arizona, United States

🇺🇸

CSG Investigational Site (#150), Phoenix, Arizona, United States

and more 134 locations

Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes

Phase 2
Completed
Conditions
Diabetic Nephropathy
Interventions
First Posted Date
2008-08-14
Last Posted Date
2015-10-28
Lead Sponsor
NephroGenex, Inc.
Target Recruit Count
317
Registration Number
NCT00734253
Locations
🇺🇸

The Collaborative Study Group, Chicago, Illinois, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.